BRIEF published on 08/31/2026 at 07:05, 12 days 6 hours ago Advicenne withdraws the application for registration of ADV7103 in the United States FDA Pharmaceutical Registration Advicenna Sibnayal
BRIEF published on 08/31/2026 at 07:05, 12 days 6 hours ago Advicenne retire la demande d'enregistrement d'ADV7103 aux États-Unis FDA Pharmaceutique Advicenne Sibnayal Enregistrement
PRESS RELEASE published on 08/31/2026 at 07:00, 12 days 6 hours ago Inside Information / Other news releases Advicenne voluntarily withdraws NDA for ADV7103 in the USA due to CMC-related work issues. Company hosting French webinar for shareholders. ADV7103 approved in EU, UK, KSA, UAE Pharmaceutical Webinar Advicenne ADV7103 NDA Withdrawal
PRESS RELEASE published on 08/31/2026 at 07:00, 12 days 6 hours ago Informations privilégiées / Autres communiqués Advicenne retire la demande d'enregistrement de ADV7103 aux Etats-Unis pour le traitement de l'Acidose Tubulaire Rénale distale primaire, en raison de travaux complémentaires requis dans le domaine CMC Advicenne Retrait ADV7103 Acidose Tubulaire Rénale Demande D'enregistrement
BRIEF published on 07/16/2026 at 18:40, 1 month 26 days ago Advicenne's Revenue Surge in First Half of 2026 Revenue Growth Advicenne Sibnayal® Likozam® Pharmaceutical Sales
BRIEF published on 07/16/2026 at 18:40, 1 month 26 days ago Forte hausse du chiffre d'affaires d'Advicenne au premier semestre 2026 Croissance Des Revenus Advicenne Sibnayal® Likozam® Ventes Pharmaceutiques
PRESS RELEASE published on 07/16/2026 at 18:35, 1 month 26 days ago Informations privilégiées / Autres communiqués Advicenne annonce un chiffre d'affaires net du premier semestre 2026 en forte croissance grâce au remboursement de Sibnayal® et Likozam® en France Chiffre D'affaires Croissance Advicenne Sibnayal® Likozam®
PRESS RELEASE published on 07/16/2026 at 18:35, 1 month 26 days ago Inside Information / Other news releases Advicenne reports significant revenue growth in first half of 2026 driven by Sibnayal® and Likozam® reimbursement in France, ending negative impact of early access rebates. Sales of Sibnayal® and Likozam® increased in volume Revenue Growth France Advicenne Sibnayal® Likozam®
BRIEF published on 07/01/2026 at 17:50, 2 months 10 days ago Unlimited renewal of the marketing authorization for Sibnayal® by Advicenne in the United Kingdom United Kingdom Advicenna Sibnayal Rare Kidney Diseases Marketing Authorization Renewal
BRIEF published on 07/01/2026 at 17:50, 2 months 10 days ago Renouvellement illimité de l'AMM de Sibnayal® par Advicenne au Royaume-Uni Royaume-Uni Advicenne Maladies Rénales Rares Sibnayal Renouvellement AMM
Published on 09/12/2026 at 02:35, 11 hours 12 minutes ago Gamma Resources Announces Extension of Private Placement Closing Date
Published on 09/11/2026 at 23:00, 14 hours 47 minutes ago Rio Grande Resources Engages Machai Capital for Investor Outreach
Published on 09/11/2026 at 22:05, 15 hours 42 minutes ago Usha Resources Announces Leadership Transition
Published on 09/11/2026 at 21:25, 16 hours 22 minutes ago Algo Grande Copper Intersects 30.23 Metres Grading 1.5% CuEq, including 3.55 Metres at 9.4% CuEq and 1.2-Metre Interval at 15.8% CuEq, 100 Metres Vertical Step-Out from Historical Intersects
Published on 09/11/2026 at 17:00, 20 hours 47 minutes ago Critical Elements Selected for Canada Investment Summit Prospectus, Showcasing Project to Leading Global Investors
Published on 09/12/2026 at 07:30, 6 hours 17 minutes ago NAGRAVISION Secures Formula 1 Content for RTL Croatia and PRO PLUS Slovenia
Published on 09/11/2026 at 22:15, 15 hours 32 minutes ago Amrize Appoints Mario Gross as President of Building Envelope
Published on 09/11/2026 at 22:10, 15 hours 37 minutes ago Quantinuum to Participate in the Piper Sandler 5th Annual Growth Frontiers Conference
Published on 09/11/2026 at 19:44, 18 hours 2 minutes ago DocMorris announces final conversion price and issue size of its New Convertible Bonds due 2031
Published on 09/11/2026 at 18:15, 19 hours 32 minutes ago CGTN: How BRICS creates new opportunities for Global South development
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNOUNCES COMPLETION OF €5.3 MILLION CAPITAL INCREASE TO FUND ITS PHASE 2 TRIAL IN OBESITY
Published on 09/11/2026 at 07:00, 1 day 6 hours ago BIOPHYTIS ANNONCE LA RÉALISATION D’UNE AUGMENTATION DE CAPITAL DE 5,3 MILLIONS D’EUROS DESTINÉE À FINANCER SON ESSAI DE PHASE 2 DANS L’OBÉSITÉ
Published on 09/10/2026 at 19:30, 1 day 18 hours ago Availability of the 2026 Interim Financial Report
